Description
PrymaLab · Research use only
Preloaded Autoinjector | Livagen | 3ml Pen | 20mg
Livagen (KEDA) in bacteriostatic water, 20 mg in a preloaded 3 mL pen
Livagen, the Khavinson tetrapeptide Lys-Glu-Asp-Ala (KEDA), comes in this listing as a ready-made solution in a preloaded pen: 20 mg of Livagen in a 3 mL glass cartridge, which the safety data sheet gives as 0.67% w/v in bacteriostatic water. The research behind the name is modest. Most of it describes chromatin changes in lymphocytes cultured from elderly donors, reported by Khavinson’s St Petersburg institute and a cytogenetics group that has published with it.
Specifications
| Property | Value |
|---|---|
| Compound | Livagen (Lys-Glu-Asp-Ala (KEDA)) |
| CAS number | Not assigned |
| Molecular formula | C18H31N5O9 |
| Contents | Livagen: 20 mg per 3 mL pen (0.67% w/v) |
| Form | Sterile aqueous solution in bacteriostatic water (0.9% benzyl alcohol), supplied in a 3 mL glass cartridge inside a preloaded autoinjector pen fitted with a needle |
| Storage, sealed | Store at 2–8 °C in the original carton, protected from light |
| Safety data sheet | PL-SDS-103 |
What is in the pen
Each pen carries a 3 mL cartridge of sterile solution containing 20 mg of Livagen, the same KEDA sequence sold as powder in the Livagen 20 mg vial. At 0.67% w/v that works out to about 6.7 mg/mL. The solvent is bacteriostatic water with 0.9% benzyl alcohol. The safety data sheet leaves the peptide unclassified; for benzyl alcohol it lists acute toxicity if swallowed or inhaled, serious eye irritation and skin sensitisation.
Store the pen in its original carton at 2 to 8 °C and away from light, keep it capped once in use, and never freeze it. A pen whose solution has frozen, changed colour or gone cloudy should be discarded. The peptide pen vs vial article sets out the general differences between the two formats.
What the research covers
Livagen’s measured effects are cytogenetic. Khavinson, Lezhava and Malinin exposed leukocytes from donors aged 75 to 88 to five short peptides and reported that all of them activated ribosomal genes and decondensed tightly packed chromatin; Livagen also decondensed pericentromeric chromatin on chromosome 1 and changed chromosome 9 as well1. Lezhava and Jokhadze later reported that it reactivated condensed chromatin in lymphocytes from people over 80 and lowered the number of chromosomal changes that cobalt chloride produced in those cells2.
Both were culture studies of donated cells. None of the work involved a solution stored the way this pen is, and the abstracts say nothing about how KEDA holds up in water, so the safety data sheet’s storage conditions are the only guide for the pen. No liver experiment, animal study or human trial of Livagen appears in these references, and the papers come from a small circle of authors. The Livagen guide lists every indexed study, including the one rat study and the one liver paper, with what each measured.
How each lot is tested
Every lot is tested in PrymaLab’s own laboratory in Ashland, Kentucky before release: RP-HPLC for purity, LC-MS for identity, Karl Fischer titration for water, LAL for endotoxin and USP <71> for sterility. Published certificates are listed on the results page and can be checked by number and key on the verify page. The certificate covers the peptide lot used to fill the pen, not the finished solution. These are in-house results from PrymaLab Analytical, not an independent test, and the lab is not accredited to ISO 17025. The third-party testing guarantee on this page still applies: if any independent laboratory finds the wrong compound, or less than the stated purity or amount, the order is refunded and the cost of the test is reimbursed.
Frequently asked questions
How does the Livagen pen differ from the vial?
Both contain 20 mg of the same KEDA peptide. The vial is freeze-dried powder stored at −20 °C until the lab dissolves it; the pen is already in solution at about 6.7 mg/mL and is stored at 2 to 8 °C. The vial leaves solvent and concentration to the lab, while the pen fixes both.
What does the certificate for the pen cover?
The certificate belongs to the peptide lot that was used to fill the pen, and it describes that material rather than the solution in the cartridge. Look up the lot on the testing results page and confirm the certificate on the verify page.
Is there stability data for Livagen in solution?
None of the studies cited here measured it. The chromatin papers exposed cells to the peptide in culture and report nothing on shelf life in water, so the cold, dark, unfrozen storage on the safety data sheet is the guidance to follow.
Can the pen be used in people?
No. The Livagen pen is supplied for laboratory research only. Livagen is not an approved drug in any country, and the pen must not be used in people or animals.
References
- Khavinson VKh, Lezhava TA, Malinin VV. Effects of short peptides on lymphocyte chromatin in senile subjects. Bull Exp Biol Med. 2004;137(1):78-81. DOI · PubMed
- Lezhava T, Jokhadze T. Activation of pericentromeric and telomeric heterochromatin in cultured lymphocytes from old individuals. Ann N Y Acad Sci. 2007;1100:387-99. DOI · PubMed
Research use only
For laboratory research use only. This product is not a drug, food, cosmetic or dietary supplement, is not approved by the FDA or any comparable authority for human or veterinary use, and must not be given to people or animals. It is sold to qualified researchers and institutions, and the buyer is responsible for lawful handling and disposal.
Other formats of Livagen
Livagen is also stocked as Livagen 20mg Nasal Spray. Each listing states its own quantity and concentration, and the pen and vial comparison explains what changes between formats.
Reviews
There are no reviews yet.